company background image
GBIO logo

Generation Bio NasdaqGS:GBIO Stock Report

Last Price

US$3.42

Market Cap

US$227.5m

7D

3.0%

1Y

-31.0%

Updated

13 Jun, 2024

Data

Company Financials +

Generation Bio Co.

NasdaqGS:GBIO Stock Report

Market Cap: US$227.5m

GBIO Stock Overview

Develops non-viral genetic medicines for the treatment of rare and prevalent diseases.

GBIO fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Generation Bio Co. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Generation Bio
Historical stock prices
Current Share PriceUS$3.42
52 Week HighUS$6.98
52 Week LowUS$0.86
Beta2.87
1 Month Change-3.39%
3 Month Change10.68%
1 Year Change-31.05%
3 Year Change-86.65%
5 Year Changen/a
Change since IPO-86.15%

Recent News & Updates

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Recent updates

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

May 01
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Dec 07
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

Jul 11
Companies Like Generation Bio (NASDAQ:GBIO) Can Afford To Invest In Growth

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Mar 11
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

Nov 19
Generation Bio (NASDAQ:GBIO) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Aug 05
We're Hopeful That Generation Bio (NASDAQ:GBIO) Will Use Its Cash Wisely

Generation Bio GAAP EPS of -$0.66 misses by $0.04

Aug 04

Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Apr 20
Companies Like Generation Bio (NASDAQ:GBIO) Are In A Position To Invest In Growth

Generation Bio: High-Risk, Medium-To-Low-Reward

Dec 30

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Nov 11
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Jul 28
We Think Generation Bio (NASDAQ:GBIO) Can Afford To Drive Business Growth

Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Mar 08
Here's Why We're Not Too Worried About Generation Bio's (NASDAQ:GBIO) Cash Burn Situation

Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Jan 14
Trade Alert: The Independent Director Of Generation Bio Co. (NASDAQ:GBIO), Charles Rowland, Has Just Spent US$500k Buying 25% More Shares

Generation Bio's insiders on buying spree, stock +4%

Jan 13

Generation Bio prices equity offering at $24.50

Jan 07

Generation Bio files to offer 7.5M shares

Jan 04

Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Dec 27
Should You Take Comfort From Insider Transactions At Generation Bio Co. (NASDAQ:GBIO)?

Generation Bio EPS misses by $0.01

Nov 10

Shareholder Returns

GBIOUS BiotechsUS Market
7D3.0%0.2%1.0%
1Y-31.0%8.4%21.8%

Return vs Industry: GBIO underperformed the US Biotechs industry which returned 8.4% over the past year.

Return vs Market: GBIO underperformed the US Market which returned 21.8% over the past year.

Price Volatility

Is GBIO's price volatile compared to industry and market?
GBIO volatility
GBIO Average Weekly Movement14.8%
Biotechs Industry Average Movement10.4%
Market Average Movement5.8%
10% most volatile stocks in US Market15.6%
10% least volatile stocks in US Market2.9%

Stable Share Price: GBIO's share price has been volatile over the past 3 months.

Volatility Over Time: GBIO's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2016174Geoff McDonoughgenerationbio.com

Generation Bio Co. develops non-viral genetic medicines for the treatment of rare and prevalent diseases. The company develops cell-targeted lipid nanoparticle (ctLNP) platform, a modular delivery system for nucleic acids to avoid off-target clearance by the liver and spleen that enables ctLNPs to persist in systemic circulation, which allows for highly selective and potent ligand-driven targeting to specific tissues and cell types; and novel immune-quiet DNA (iqDNA) to enable long-lasting high levels of gene expression from non-integrating episomes and avoids innate immune sensors that have long prevented DNA from use in non-viral systems. It uses its platform for developing a portfolio of programs for treating cancer, autoimmune, hematologic disorders, prioritizing sickle cell, beta-thalassemia, and hemophilia A diseases, as well as for other tissues and cell types, including retina, skeletal muscle, and central nervous system.

Generation Bio Co. Fundamentals Summary

How do Generation Bio's earnings and revenue compare to its market cap?
GBIO fundamental statistics
Market capUS$227.53m
Earnings (TTM)-US$169.06m
Revenue (TTM)US$9.96m

22.8x

P/S Ratio

-1.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
GBIO income statement (TTM)
RevenueUS$9.96m
Cost of RevenueUS$71.98m
Gross Profit-US$62.01m
Other ExpensesUS$107.04m
Earnings-US$169.06m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-2.54
Gross Margin-622.45%
Net Profit Margin-1,696.87%
Debt/Equity Ratio0%

How did GBIO perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.